SHANGHAI -- (BUSINESS WIRE) --
Mallinckrodt Pharmaceuticals today announced a partnership with China Resources Pharmaceutical (Shanghai) Co., Ltd. for the promotion of Optiray™ (ioversol injection) x-ray contrast media in the People’s Republic of China (PRC).
“Through this collaboration with China Resources Pharmaceutical, Mallinckrodt looks forward to increasing our ongoing commitment to grow sales of imaging products in the PRC,” said Stephen Merrick, President, International Commercial Operations at Mallinckrodt. “Contrast media products to be covered under this agreement will be used for X-ray, computed tomography or cardiovascular procedures.”
Optiray (ioversol injection) x-ray contrast media is a non-ionic, low viscosity iodine based contrast medium that is administered through intravascular routes to enhance diagnostic imaging procedures. China Resources Pharmaceutical is uniquely positioned to take the Optiray business in China to new levels through a combination of broad customer coverage, professionalism and specific expertise in the imaging segment within the PRC.
This agreement is effective immediately and efforts are currently underway to transition from the previous promoter based model in China.
About Mallinckrodt
Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 70 countries. The company’s 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
About China Resources Pharmaceutical Group Limited
Enterprise group founded at the request of “Establishing state-owned medical enterprise platform” by State-owned Assets Supervision and Administration Commission of the State Council (SASAC),dedicated to R&D, manufacture, and distribution of pharmaceutical products in China, and one of the seven core strategic business units of China Resources (Holding) Co., Ltd. By the end of 2012, total assets had reached HKD 85.6 billion, with annual revenue of HKD 98.6 billion and operating profit of HKD 6.16 billion, ranked Top 3 in China's pharmaceutical industry. For more information, visit http://www.crc.com.cn/eng2012/index.htm.
CONTACT:
Mallinckrodt Pharmaceuticals:
Lynn Phillips, 314-654-3263
Media Relations
lynn.phillips@mallinckrodt.com
or
John Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com
or
China Resources Pharmaceutical (Shanghai) Co., Ltd.:
Chengming Xu
Senior Manager of Marketing Dept.
+86 21 6288-3993
xucm1957@gmail.com